ClinicalTrials.gg
CompletedNCT02170935Updated Jun 23, 2014

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

A Phase 2 interventional study of BIBR 1048 capsule in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-23.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
12th of 17
62 · median 148
Started
2002
with 1 other
Phase 2
7 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 12th largest by enrollment, is one of 2 that started in 2002, is one of 7 in phase 2, and was the 11th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

To determine the PK profile of a single dose 150 mg BIBR 1048, oral capsule, administered 1-3 hours post surgery in hip replacement patients.

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled to undergo a primary elective total hip replacement
  • Male or female being 18 years or older (women of child bearing potential may not be included)
  • Patients weighing at least 40 kg
  • Written for participation

Exclusion criteria

Exclusion Criteria:

  • Bleeding disorders, e.g. history of intracranial, intraocular, gastrointestinal or pulmonary bleeding, known thrombocytopenia, history of haemorrhagic stroke
  • Known renal disease
  • Known liver disease, alcohol or drug misuse
  • Known
  • Treatment with another study drug in the past month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    BIBR 1048 capsule

    Drug: BIBR 1048 capsule

Interventions

06

What researchers measure

Primary outcomes

  1. maximum plasma concentration (Cmax)

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

  2. time to maximum plasma concentration (Tmax)

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

  3. total clearance of drug from plasma

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

  4. terminal elimination constant

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

  5. time of last measureable BIBR 953 ZW plasma concentration (Tf)

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

  6. area under the plasma concentration time curve until Tf (AUC0-Tf)

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

  7. area under the plasma concentration time extrapolated to infinity (AUC0-infinity)

    Time frame: pre dose, 1, 2, 4, 6-8, 10-18 and 24 hours post dose

Secondary outcomes

  1. Occurrence of adverse events

    Time frame: up to 24 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002 and a primary completion of Jun 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 23, 2014
Start
Apr 2002
Primary completionActual
Jun 2002
Last update
Jun 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02170935
Responsible party
Sponsor
First posted
Jun 23, 2014
Start date
Apr 2002
Primary completion
Jun 2002
Last update
Jun 23, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion